Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 (Camrelizumab) in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT03558191Phase 2Completed
- Sponsor
- Hengrui
- Start
- Aug 2018
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Hengrui. Started Aug 2018; status: completed.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03558191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03558191.